# Context Therapeutics Inc.: Form 10-Q for the period ended Sep 30, 2021

- Company: [Context Therapeutics Inc.](/companies/cntx.md) (CIK 1842952)
- Form: 10-Q
- Filed: 2021-12-02
- Accepted by EDGAR: Dec 2, 2021, 16:06 ET
- Period: 2021-09-30
- Accession: 0001842952-21-000015
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1842952/000184295221000015/cntx-20210930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1842952/000184295221000015/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Operating income | 3 months, 2021-07-01 to 2021-09-30 | −$1.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2021-01-01 to 2021-09-30 | −$7.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2021-07-01 to 2021-09-30 | $1.3k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2021-01-01 to 2021-09-30 | $64.6k | us-gaap:InterestExpense |
| Net income | 3 months, 2021-07-01 to 2021-09-30 | −$1.4m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2021-01-01 to 2021-09-30 | −$7.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2021-07-01 to 2021-09-30 | −$4.00 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2021-01-01 to 2021-09-30 | −$20.74 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2021-07-01 to 2021-09-30 | −$4.00 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2021-01-01 to 2021-09-30 | −$20.74 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2021-07-01 to 2021-09-30 | 361,067 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2021-01-01 to 2021-09-30 | 355,087 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2021-01-01 to 2021-09-30 | −$3.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2021-09-30 | $419.2k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-09-30 | $437.5k | us-gaap:AssetsCurrent |
| Total assets | at 2021-09-30 | $2.3m | us-gaap:Assets |
| Current liabilities | at 2021-09-30 | $4.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2021-09-30 | $4.4m | us-gaap:Liabilities |
| Shareholders' equity | at 2021-09-30 | −$23.2m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 1,577 characters.

#### Use of Proceeds

Our IPO was effected through a Registration Statement on Form S-1 (File No. 333-256572) that was declared effective by the SEC on October 19, 2021. On October 22, 2021, 5,750,000 shares of our common stock were sold at a price to the public of $5.00 per share, for aggregate gross proceeds of $28.75 million. As of the date of filing this report, the offering has terminated, and all of the securities registered pursuant to the offering were sold prior to termination. ThinkEquity LLC acted as the underwriter of this offering.

We paid to the underwriter underwriting discounts and commissions of approximately $2.5 million in connection with the offering. In addition, we incurred expenses of approximately $1.8 million in connection with the offering. Thus, the net offering proceeds to us, after deducting underwriting discounts and commissions and offering expenses, were approximately $24.4 million. The net proceeds shall be used in a manner consistent with the use of proceeds from the IPO as described in the Prospectus under “Use of Proceeds.”

The foregoing expenses are a reasonable estimate of the expenses incurred by us in the offering and do not represent the exact amount of expenses incurred. All of the foregoing expenses were direct or indirect payments to persons other than (i) our directors, officers or any of their associates; (ii) persons owning 10% or more of our common stock; or (iii) our affiliates.

There has been no material change in the use of proceeds from the IPO as described in the Prospectus under “Use of Proceeds.”

## Market risk

As filed, 165 characters.

We are a smaller reporting company as defined in Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this Item 3.

## Controls and procedures

As filed, 1,771 characters.

Under the supervision and with the participation of our management, including our principal executive officer and

principal financial officer, we conducted an evaluation of the design and operation of our disclosure controls and procedures, as

such term is defined in Rule 13a-15(e) and 15d-15(e) promulgated under the Exchange Act, as of the end of the period covered

by this Quarterly Report. During the preparation of our consolidated financial statements for the years ended December 31, 2019 and 2020, we and our independent registered public accounting firm identified a material weakness related to the lack of an appropriate review of the internally prepared financial statements which resulted in the Company’s failure to timely detect and correct certain misstatements within the consolidated financial statements. Such misstatements were corrected in the consolidated financial statements for the years ended December 31, 2019 and 2020. We also identified a material weakness as it relates to a lack of adequate segregation of accounting functions.

We are in the process of implementing measures designed to improve our internal control over financial reporting to remediate these material weaknesses. Our plan to remediate the material weaknesses in our internal control over financial reporting includes utilizing a portion of the working capital from our initial public offering to increase staffing within our accounting infrastructure sufficient to facilitate proper segregation of accounting functions and to enable appropriate review of our internally prepared consolidated financial statements. In addition, we plan to retain outside consultants, expert in, and specializing in technical accounting and SEC reporting for public company registrants.

## Risk factors

As filed, 882 characters.

Investing in our common stock involves a high degree of risk. In addition to the other information set forth in this quarterly report on Form 10-Q, you should carefully consider the factors described in Part I, Item 1A. “Risk Factors” of our prospectus dated October 19, 2021, filed with the SEC pursuant to Rule 424(b) under the Securities Act (Prospectus). There have been no material changes to the risk factors described in that report. The occurrence of any of the events or developments described in our Risk Factors could adversely affect our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.

Filed Dec 2, 2021.
Source: SEC EDGAR, the filing index for accession 0001842952-21-000015. Last ingested by Listed: Nov 11, 2026, 01:22 ET. No prices; not investment advice.
